ImmiPrint® Diagnostic Technology
Cluster of differentiation (CD) antigens are proteins that are present on the cell surface of white blood cells and on a variety of other tissue types. They play a key role in cell signalling as well as having a number of other functions. These include the facilitation of cell adhesion and functioning as cell surface receptors. Around 350 CD antigens have been identified to date in humans, and new CD antigens are still being discovered. Many of the CD antigens play an important role in regulating immune responses.
CD antigens were discovered by Dr César Milstein (Nobel Prize winner, inventor of monoclonal antibodies and co-inventor of ImmiPrint® technology) at the MRC Laboratory of Molecular Biology in Cambridge, UK. Milstein subsequently demonstrated that human cell surface CD antigens are released into the bloodstream as soluble forms, which are shed or in some cases made by alternative gene splicing. In collaboration with colleagues in the Cambridge University Clinical Biochemistry Department, Milstein subsequently showed that patterns of soluble CD antigens (sCDs) in the blood appear to correlate with the presence of specific diseases. This led to the idea that patterns of sCD proteins could be used as the basis of a generalized system that could be used for the diagnosis of multiple different disease types.
ProteinLogic has reduced this concept to practice by identifying preliminary sCD patterns (ImmiPrints®) for 14 different diseases representing several different disease types.
ProteinLogic has combined its novel, rational, and discreet protein content solution with high throughput automated immunoassay technology and pattern recognition software to generate a generic biomarker search and discovery platform that has the potential to transform clinical diagnostics.
Through the construction of databases of disease-specific proteomic sCD fingerprints coupled to corresponding clinical databases, disease-specific diagnostic fingerprints can be defined.
The advantages of ImmiPrint® technology include:
- Simplification of the biomarker discovery process through the profiling of a discreet set of immune system (sCD) proteins
- High diagnostic sensitivity and specificity
- Provision of a generic ‘one size fits all’ approach to biomarker discovery
- Reduced development and validation time due to the availability of multiple high quality sCD reagents
- Delivery of rapid and inexpensive blood tests that have the potential to outperform existing methods and to address significant unmet medical needs
- Applicability to a wide range of different diseases